- This May 1, 2018, shows Merck corporate headquarters in Kenilworth, N.J. RAHWAY, Nj – In its fourth quarter report, Merck, the giant pharmaceutical company with multiple facilities in eastern ...

Rory Londer's third "walk of gratitude" around the Mayo Clinic campus coincides with an expansion of support services for ...

During a Q1 earnings call, Merck CEO Rob Davis discussed pipeline diversification plans and effects of tariffs on its ...

Summit Therapeutics (NASDAQ:SMMT) traded higher for the fifth straight session on Thursday as investors continued to cheer ...

MRK posts better-than-expected first-quarter results but trims its 2025 EPS outlook due to anticipated one-time charges.

Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid a roiling trade war between the US ...

The company’s stock fell as much as 2.8% after markets opened in New York Thursday. For the first quarter, Merck’s results ...

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

Akeso Pharmaceuticals and Summit Therapeutics have reported that their PD-1/VEGF bispecific antibody has met the primary ...

Merck said the expected tariff charge primarily reflects levies between the U.S. and China, but does not account for Trump’s ...

Ivonescimab plus chemotherapy improved survival in advanced squamous NSCLC vs tislelizumab and chemotherapy in a phase 3 ...

Akeso and Summit Therapeutics’ giant-killing, PD-1xVEGF bispecific antibody ivonescimab has posted another phase 3 trial win ...